Scarica l'app Stockscreener
369.14
3.82%
13.57
Dopo l'orario di chiusura:
369.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
Bio-Rad Laboratories Drops 5.2% Amid Sector-Wide Selling - AlphaStreet
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Why Bio Rad Laboratories (BIO) Is Back In The Spotlight - Yahoo Finance
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - TradingView
Bio-Rad Laboratories, Inc. (BIO) stock price, news, quote and history - Yahoo Finance Australia
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bio-Rad Laboratories (HAM:BUWA) Net Intangibles Purchase An - GuruFocus
Q1 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
RBC Capital reiterates Bio-Rad Labs stock rating on transformation outlook - Investing.com Nigeria
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032 - GlobeNewswire Inc.
Bio-Rad Laboratories Inc Stock Warning Signs - GuruFocus
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth - Yahoo Finance
Bio-Rad Laboratories Inc. Class A (BIO) Key Financial Ratios – Valuation, Profitability & More - Value Research
BIO: Multi-year transformation leverages technology, M&A, and restructuring to drive growth and margin expansion - TradingView
BIO: Multi-year transformation leverages digital PCR leadership and targeted M&A for growth - TradingView
Bio-Rad at bernstein healthcare forum: shift toward profitable growth - Investing.com
Bio-Rad at bernstein healthcare forum: shift toward profitable growth By Investing.com - Investing.com Canada
Bio-Rad Laboratories, Inc. at Bernstein Insights Healthcare Leaders and Disruptors Transcript - GuruFocus
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher - Yahoo Finance
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher - Investing.com
Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher By Investing.com - Investing.com India
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher - Quiver Quantitative
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring - The Manila Times
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - TradingView
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Challenges in the Medical Devices Sector - DirectorsTalk Interviews
Bio-rad Laboratories Stock Price Forecast. Should You Buy BIO? - StockInvest.us
Accelerating Legacy .NET Modernization at Bio-Rad with AWS Transform and Kiro - Amazon Web Services (AWS)
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues - Yahoo Finance
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - Manufacturing Chemist
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
0.26%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):